Skip to main content

Table 3 Baseline characteristics according to prior biologic therapy use

From: Real-life experience with benralizumab during 6 months

Variables Biologic treatment-naïve patients
(n = 20)
Patients with prior biologic therapy
(n = 22)
p
Age, years; md (IR) 58 (20.75) 52 (14.75) 0.089
Women, n (%) 16 (80) 17 (77.3) 1
BMI, md (IR) 28 (6.75) 27.5 (8.5) 0.980
Age at diagnosis, years; md (IR) 30 (24) 22.5 (14) 0.079
Atopy, n (%) 2 (10) 12 (54.5) 0.01
Corticosteroid-dependent, n (%) 7 (35) 10 (46) 0.708
Nasal polyps, n (%) 3 (15) 9 (41) 0.130
AERD, n (%) 0 (0) 6 (27) 0.022
ACT, md (IR) 14 (6) 13.5 (6) 0.430
ED visits in the previous year; md (IR) 5 (2) 3 (6) 0.325
Cycles of OCS in the previous year; md (IR) 7 (2) 5 (7) 0.155
Oral prednisone (or equivalent) dose, mg/day; md (IR) 20 (15) 17.5 (20) 0.579
Post-BD FEV1, mL; md (IR) 1420 (835) 1445 (913) 0.980
Post-BD FEV1, %; md (IR) 65 (13) 66.5 (16) 0.404
FeNO, ppb; md (IR) 66 (32) 60 (60) 0.351
Blood eosinophil count, cells/μL; md (IR) 755 (315) 660 (205) 0.177
IgE, IU/mL; md (IR) 43.5 (40) 216 (288) < 0.001
  1. Abbreviations: ACT Asthma Control Test, AERD Aspirin-exacerbated respiratory disease, BD Bronchodilator, BMI Body mass index, ED Emergency department, FeNO Fractional exhaled nitric oxide, FEV1 Forced expiratory volume in 1 s, IR Interquartile range, md Median, ppb Parts per billion, OCS Oral corticosteroids